Celyad VP talks IP issues, development timelines for CAR-T therapies

April 13, 2017 Christoph Graener

Georges Rawadi, VP of business development and intellectual property at Celyad, discusses the company’s CAR-T pipeline, recently resolved IP issues and the firm’s strategy for future clinical development. At the recent BIO-Europe Spring partnering meeting in Barcelona, Rawadi told Scrip more about how Celyad’s technology will compete with other treatments coming through the immuno-oncology development pipeline and the next big milestones for the business.

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Georges Rawadi – VP Business Development and IP, Celyad

Previous Article
Atriva repurposes cancer drug candidates to create universal flu treatment

Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, explains how his company is taking kinase inhibitors ...

Next Article
Noxxon CEO discusses partners and cancer combinations

Aram Mangasarian, CEO of Noxxon Pharma, a biotech company focused on cancer therapies targeting the tumor m...